Circulating tumor cells in uveal melanoma

Future Oncology

Volumn 7, Issue 1, 2011, Pages 101-109

  Torres, Virginia ^a   Triozzi, Pierre ^b   Eng, Charis ^b   Tubbs, Raymond ^b   Schoenfiled, Lynn ^b   Crabb, John W ^b   Saunthararajah, Yogen ^b   Singh, Arun D ^a,b  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

biopsy; cutaneous melanoma; diagnosis; melanoma; metastasis; prognosis; uveal melanoma

Indexed keywords

GLYCOPROTEIN GP 100; MELAN A; MESSENGER RNA; MONOPHENOL MONOOXYGENASE;

ARTICLE; BRACHYTHERAPY; CANCER GROWTH; CANCER SURGERY; CANCER SURVIVAL; DIAGNOSTIC ACCURACY; DRUG EFFICACY; ENUCLEATION; HUMAN; IMMUNOMAGNETIC SEPARATION; LIVER METASTASIS; MELANOMA; MELANOMA CELL; METASTASIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TRANSPUPILLARY THERMOTHERAPY; TUMOR CELL; UVEA MELANOMA;

EARLY DETECTION OF CANCER; HUMANS; MELANOMA; NEOPLASTIC CELLS, CIRCULATING; POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; UVEAL NEOPLASMS;

EID: 78650589136     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.143     Document Type: Article

References (75)

1. Singh AD, Topham A: Incidence of uveal melanoma in the United States: 1973-1997. Ophthalmology 110(5), 956-961 (2003).
2. Triozzi PL, Eng C, Singh AD: Targeted therapy for uveal melanoma. Cancer Treat. Rev. 34(3), 247-258 (2008).
3. Design and methods of a clinical trial for a rare condition: the Collaborative Ocular Melanoma Study. COMS Report No. 3. Control. Clin. Trials 14(5), 362-391 (1993).
4. Clinical Ophthalmic Oncology. Singh AD, Damato BE, Pe'er J, Murphree AL, Perry JD (Eds.) Saunders-Elsevier, Philadelphia, PA, USA (2007).
5. Lorigan JG, Wallace S, Mavligit GM: The prevalence and location of metastases from ocular melanoma: imaging study in 110 patients. Am. J. Roentgenol. 157(6), 1279-1281 (1991).
6. Singh AD, Borden EC: Metastatic uveal melanoma. Ophthalmol. Clin. North Am. 18(1), 143-150, IX (2005).
7. Augsburger JJ, Correa ZM, Shaikh AH: Effectiveness of treatments for metastatic uveal melanoma. Am. J. Ophthalmol. 148(1), 119-127 (2009).
8. Dorval T, Desjardins L, Tournet I et al.: Lack of effcacy of adjuvant chemotherapy (dacarbazine) in patients with choroidal melanoma: a prospective randomized study. Presented at: 1997 ASCO Annual Meeting. Denver CO, USA, 17-20 May 1997
9. Diener-West M, Reynolds SM, Agugliaro DJ et al.: Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch. Ophthalmol. 123(12), 1639-1643 (2005).
10. Singh AD: Uveal melanoma: implications of tumor doubling time. Ophthalmology 108(5), 829-831 (2001).
11. Diener-West M, Earle JD, Fine SL et al.: The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality fndings. COMS Report No. 18. Arch. Ophthal. 119(7), 969-982 (2001).
12. Mudhar HS, Parsons MA, Sisley K, Rundle P, Singh A, Rennie IG: A critical appraisal of the prognostic and predictive factors for uveal malignant melanoma. Histopathology 45(1), 1-12 (2004).
13. Al-Jamal RT, Makitie T, Kivela T: Nucleolar diameter and microvascular factors as independent predictors of mortality from malignant melanoma of the choroid and ciliary body. Invest. Ophthalmol. Vis. Sci. 44(6), 2381-2389 (2003).
14. Prescher G, Bornfeld N, Becher R: Nonrandom chromosomal abnormalities in primary uveal melanoma. J. Natl Cancer Inst. 82(22), 1765-1769 (1990).
15. Patel KA, Edmondson ND, Talbot F, Parsons MA, Rennie IG, Sisley K: Prediction of prognosis in patients with uveal melanoma using fuorescence in situ hybridisation. Br. J. Ophthal. 85(12), 1440-1444 (2001).
16. Sisley K, Rennie IG, Parsons MA et al.: Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis. Genes Chromosomes Cancer 19(1), 22-28 (1997).
17. Desjardins L, Levy-Gabriel C, Lumbroso-Lerouic L et al.: Prognostic factors for malignant uveal melanoma. Retrospective study on 2,241 patients and recent contribution of monosomy-3 research. J. Francais D'op hta lmo logie 29 (7), 741-749 (2006).
18. Scholes AG, Damato BE, Nunn J, Hiscott P, Grierson I, Field JK: Monosomy 3 in uveal melanoma: correlation with clinical and histologic predictors of survival. Invest. Ophthal. Visual Sci. 44(3), 1008-1011 (2003).
19. Tschentscher F, Husing J, Holter T et al.: Tumor classifcation based on gene expression profling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res. 63(10), 2578-2584 (2003).
20. Onken MD, Worley LA, Ehlers JP, Harbour JW: Gene expression profling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 64(20), 7205-7209 (2004).
21. Petrausch U, Martus P, Tonnies H et al.: Signifcance of gene expression analysis in uveal melanoma in comparison to standard risk factors for risk assessment of subsequent metastases. Eye (Lond.) 22(8), 997-1007 (2008).
22. Singh AD, Sisley K, Xu Y et al.: Reduced expression of autotaxin predicts survival in uveal melanoma. Br. J. Ophthal. 91(10), 1385-1392 (2007).
23. Worley LA, Long MD, Onken MD, Harbour JW: micro-RNAs associated with metastasis in uveal melanoma identifed by multiplexed microarray profling. Melanoma Res. 18(3), 184-190 (2008).
24. Onken MD, Worley LA, Tuscan MD, Harbour JW: An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J. Mol. Diagn. 12(4), 461-468 (2010).
25. Midena E, Bonaldi L, Parrozzani R, Radin PP, Boccassini B, Vujosevic S: In vivo monosomy 3 detection of posterior uveal melanoma: 3-year follow-up. Graefes Arch. Clin. Exp. Ophthalmol. 246(4), 609-614 (2008).
26. Shields CL, Ganguly A, Materin MA et al.: Chromosome 3 analysis of uveal melanoma using fne-needle aspiration biopsy at the time of plaque radiotherapy in 140 consecutive cases: the Deborah Iverson, MD, Lectureship. Arch. Ophthalmol. 125(8), 1017-1024 (2007).
27. Budd GT: Let me do more than count the ways: what circulating tumor cells can tell us about the biology of cancer. Mol. Pharm. 6(5), 1307-1310 (2009).
28. Callejo SA, Antecka E, Blanco PL, Edelstein C, Burnier MN Jr: Identifcation of circulating malignant cells and its correlation with prognostic factors and treatment in uveal melanoma. A prospective longitudinal study. Eye (Lond.) 21(6), 752-759 (2007).
29. Alunni-Fabbroni M, Sandri MT: Circulating tumour cells in clinical practice: methods of detection and possible characterization. Methods 50(4), 289-297 (2010).
30. Steen S, Nemunaitis J, Fisher T, Kuhn J: Circulating tumor cells in melanoma: a review of the literature and description of a novel technique. Proc. (Bayl. Univ. Med. Cent.) 21(2), 127-132 (2008).
31. Miller MC, Doyle GV, Terstappen LW: Signifcance of circulating tumor cells detected by the Cellsearch system in patients with metastatic breast colorectal and prostate cancer. J. Oncol. 617421 (2010).
32. Mouawad R, Spano JP, Khayat D: Old and new serological biomarkers in melanoma: where we are in 2009. Melanoma Res. 20(2), 67-76 (2010).
33. Benez A, Geiselhart A, Handgretinger R, Schiebel U, Fierlbeck G: Detection of circulating melanoma cells by immunomagnetic cell sorting. J. Clin. Lab. Anal. 13(5), 229-233 (1999).
34. Ulmer A, Schmidt-Kittler O, Fischer J et al.: Immunomagnetic enrichment, genomic characterization, and prognostic impact of circulating melanoma cells. Clin. Cancer Res. 10(2), 531-537 (2004).
35. Smith B, Selby P, Southgate J, Pittman K, Bradley C, Blair GE: Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 338(8777), 1227-1229 (1991).
36. Thompson JF, Shaw HM, Hersey P, Scolyer RA: The history and future of melanoma staging. J. Surg. Oncol. 86(4), 224-235 (2004).
37. Foss AJ, Guille MJ, Occleston NL, Hykin PG, Hungerford JL, Lightman S: The detection of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction. Br. J. Cancer 72(1), 155-159 (1995).
38. Glaser R, Rass K, Seiter S, Hauschild A, Christophers E, Tilgen W: Detection of circulating melanoma cells by specifc amplifcation of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: a clinical two-center study. J. Clin. Oncol. 15(8), 2818-2825 (1997).
39. Reinhold U, Ludtke-Handjery HC, Schnautz S, Kreysel HW, Abken H: The analysis of tyrosinase-specifc mRNA in blood samples of melanoma patients by RT-PCR is not a useful test for metastatic tumor progression. J. Invest. Dermatol. 108(2), 166-169 (1997).
40. Farthmann B, Eberle J, Krasagakis K et al.: RT-PCR for tyrosinase-mRNA-positive cells in peripheral blood: evaluation strategy and correlation with known prognostic markers in 123 melanoma patients. J. Invest. Dermatol. 110(3), 263-267 (1998).
41. O'Connell CD, Juhasz A, Kuo C, Reeder DJ, Hoon DS: Detection of tyrosinase mRNA in melanoma by reverse transcription-PCR and electrochemiluminescence. Clin. Chem. 44(6 Pt 1), 1161-1169 (1998).
42. Brossart P, Keilholz U, Willhauck M, Scheibenbogen C, Mohler T, Hunstein W: Hematogenous spread of malignant melanoma cells in different stages of disease. J. Invest. Derm. 101(6), 887-889 (1993).
43. Battayani Z, Grob JJ, Xerri L et al.: Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patients with melanoma. Arch. Derm. 131(4), 443-447 (1995).
44. Hoon DS, Wang Y, Dale PS et al.: Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J. Clin. Oncol. 13(8), 2109-2116 (1995).
45. Hoon DS, Bostick P, Kuo C et al.: Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res. 60(8), 2253-2257 (2000).
46. Wascher RA, Morton DL, Kuo C et al.: Molecular tumor markers in the blood: early prediction of disease outcome in melanoma patients treated with a melanoma vaccine. J. Clin. Oncol. 21(13), 2558-2563 (2003).
47. Palmieri G, Ascierto PA, Perrone F et al.: Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction. J. Clin. Oncol. 21(5), 767-773 (2003).
48. Mellado B, Del Carmen Vela M, Colomer D et al.: Tyrosinase mRNA in blood of patients with melanoma treated with adjuvant interferon. J. Clin. Oncol. 20(19), 4032-4039 (2002).
49. Koyanagi K, O'Day SJ, Gonzalez R et al.: Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. J. Clin. Oncol. 23(31), 8057-8064 (2005).
50. Strohal R, Mosser R, Kittler H et al.: MART-1/Melan-A and tyrosinase transcripts in peripheral blood of melanoma patients: PCR analyses and follow-up testing in relation to clinical stage and disease progression. Melanoma Res. 11(5), 543-548 (2001).
51. Fujiwara Y, Chi DD, Wang H et al.: Plasma DNA microsatellites as tumor-specifc markers and indicators of tumor progression in melanoma patients. Cancer Res. 59(7), 1567-1571 (1999).
52. Fujimoto A, O'Day SJ, Taback B, Elashoff D, Hoon DS: Allelic imbalance on 12q22-23 in serum circulating DNA of melanoma patients predicts disease outcome. Cancer Res. 64(12), 4085-4088 (2004).
53. Taback B, O'Day SJ, Boasberg PD et al.: Circulating DNA microsatellites: molecular determinants of response to biochemotherapy in patients with metastatic melanoma. J. Natl Cancer Inst. 96(2), 152-156 (2004).
54. Mori T, O'Day SJ, Umetani N et al.: Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. J. Clin. Oncol. 23(36), 9351-9358 (2005).
55. Horodenski J: Studies on the presence of free cells of malignant melanoma of the uvea in peripheral blood. Klinika Oczna 39(3), 407-412 (1969).
56. Fernandes BF, Belfort RN, Di Cesare S, Burnier MN Jr: Circulating uveal melanoma cells: should we test for them? Can. J. Ophthalmol. 43(2), 155-158 (2008).
57. Tobal K, Sherman LS, Foss AJ, Lightman SL: Detection of melanocytes from uveal melanoma in peripheral blood using the polymerase chain reaction. Invest. Ophthal. Visual Sci. 34(9), 2622-2625 (1993).
58. El-Shabrawi Y, Langmann G, Hutter H, Kenner L, Hoefer G: Comparison of current methods and PCR for the diagnosis of metastatic disease in uveal malignant melanoma. Intl J. Ophthal. 212(1), 80 (1998).
59. Boldin I, Langmann G, Richtig E et al.: Five-year results of prognostic value of tyrosinase in peripheral blood of uveal melanoma patients. Melanoma Res. 15(6), 503-507 (2005).
60. Keilholz U, Goldin-Lang P, Bechrakis NE et al.: Quantitative detection of circulating tumor cells in cutaneous and ocular melanoma and quality assessment by real-time reverse transcriptase-polymerase chain reaction. Clin. Cancer Res. 10(5), 1605-1612 (2004).
61. Schuster R, Bechrakis NE, Stroux A et al.: Circulating tumor cells as prognostic factor for distant metastases and survival in patients with primary uveal melanoma. Clin. Cancer Res. 13(4), 1171-1178 (2007).
62. Ulmer A, Beutel J, Susskind D et al.: Visualization of circulating melanoma cells in peripheral blood of patients with primary uveal melanoma. Clin. Cancer Res. 14(14), 4469-4474 (2008).
63. Suesskind D, Ulmer A, Schiebel U et al.: Circulating melanoma cells in peripheral blood of patients with uveal melanoma before and after different therapies and association with prognostic parameters: a pilot study Acta Ophthalmologica (2009).
64. Eide N, Faye RS, Hoifodt HK et al.: Immunomagnetic detection of micrometastatic cells in bone marrow in uveal melanoma patients. Acta Ophthalmologica 87(8), 830-836 (2009).
65. Naume B, Wiedswang G, Borgen E et al.: The prognostic value of isolated tumor cells in bone marrow in breast cancer patients: evaluation of morphological categories and the number of clinically signifcant cells. Clin. Cancer Res. 10(9), 3091-3097 (2004).
66. Ring A, Smith IE, Dowsett M: Circulating tumour cells in breast cancer. Lancet Oncol. 5(2), 79-88 (2004).
67. Curry BJ, Myers K, Hersey P: Polymerase chain reaction detection of melanoma cells in the circulation: relation to clinical stage, surgical treatment, and recurrence from melanoma. J. Clin. Oncol. 16(5), 1760-1769 (1998).
68. Schrappe M, Klier FG, Spiro RC, Waltz TA, Reisfeld RA, Gladson CL: Correlation of chondroitin sulfate proteoglycan expression on proliferating brain capillary endothelial cells with the malignant phenotype of astroglial cells. Cancer Res. 51(18), 4986-4993 (1991).
69. Ozerdem U, Grako KA, Dahlin-Huppe K, Monosov E, Stallcup WB: NG2 proteoglycan is expressed exclusively by mural cells during vascular morphogenesis. Dev. Dyn. 222(2), 218-227 (2001).
70. Becker S, Becker-Pergola G, Fehm T, Wallwiener D, Solomayer EF: Time is an important factor when processing samples for the detection of disseminated tumor cells in blood/bone marrow by reverse transcription-PCR. Clin. Chem. 50(4), 785-786 (2004).
71. Jung FA, Buzaid AC, Ross MI et al.: Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients. J. Clin. Oncol. 15(8), 2826-2831 (1997).
72. Schoenfeld L, Pettay J, Tubbs RR, Singh AD: Variation of monosomy 3 status within uveal melanoma. Arch. Pathol. Lab. Med. 133(8), 1219-1222 (2009).
73. Li Y, Madigan MC, Lai K et al.: Human uveal melanoma expresses NG2 immunoreactivity. Br. J. Ophthal. 87(5), 629-632 (2003).
74. Lida J, Wilhelmson KL, Ng J et al.: Cell surface chondroitin sulfate glycosaminoglycan in melanoma: role in the activation of pro-MMP-2 (pro-gelatinase A). Biochem. J. 403(3), 553-563 (2007).
75. Pantel K, Brakenhoff RH: Dissecting the metastatic cascade. Nat. Rev. Cancer 4(6), 448-456 (2004).